Psoriasis Current Treatment: Physician Insights probes the current and future use of topical agents, phototherapy, and systemic therapies in the treatment of mild, moderate, and severe psoriasis in the EU5. It extensively examines the use of approved biologics and Otezla, including patient share, line of therapy, drivers of treatment selection, and barriers to broader uptake. The insights offered are based on primary market research with practicing dermatologists in the EU5.


  • Which patients are being prescribed which treatments?
  • What is the sequencing of treatment for psoriasis?
  • What do physicians report as recent and anticipated changes in their treatment practices?
  • What are the dermatologist-reported factors determining current prescribing patterns and recent/anticipated changes?


Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that clients can create specific messaging around these treatment dynamics in order to more effectively increase or defend their market position.

Markets covered:France, Germany, Italy, Spain, United Kingdom

Primary research: Survey of 253 dermatologists in the EU5 fielded in March 2018.

Key companies: AbbVie, Amgen, Biogen, Celgene, Celltrion, Eli Lilly, Hospira, Janssen, LEO Pharma, Novartis, Sandoz

Key drugs: Benepali, Cosentyx, Enbrel, Erelzi, Flixabi, Humira, Inflectra, Kyntheum, Otezla, Remicade, Remsima, Taltz, Tremfya

Table of contents

  • Detailed, Expanded Analysis (EU5)
    • Current Treatment: Physician Insights Psoriasis (EU5)

Author(s): Yingdee Unhavaithaya

Yingdee Unhavaithaya is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, primarily focusing on psoriasis. Prior to joining DRG, Yingdee was an analyst at Citeline, where he analyzed data on oncology clinical trials ; He was also a business development intern at the Massachusetts General Hospital Research Ventures and Licensing office, where he performed market research to look for invention licensing ; Yingdee received his in cell biology from the University of Massachusetts Medical School, and a in biology from the University of Pittsburgh at Greensburg.

Related Reports

Psoriasis | Landscape & Forecast | Disease Landscape & Forecast

The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-a...

View Details

Psoriasis | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis - Palmoplantar Pustular Psoriasis/Generalized Pustular Psoriasis (US )

MARKET OUTLOOK Pustular psoriasis is a rare subtype of psoriasis, typically seen as pustules that erupt generally across the body (generalized pustular psoriasis [GPP])...

View Details

Psoriasis | Access and Reimbursement | US | 2018

MARKET OUTLOOK In the past decade, AbbVie’s Humira and Amgen’s Enbrel tumor necrosis factor-alpha (TNF-α) inhibitors and Janssen’s interleukin (

View Details

Psoriasis | Access & Reimbursement | Detailed, Expanded Analysis (US)

MARKET OUTLOOK In the past decade, tumor necrosis factor-alpha (TNF-α) inhibitors, including AbbVie’s Humira and Amgen’s Enbr...

View Details